A Study of Avastin (Bevacizumab) Plus Xeloda (Capecitabine) in Patients With Locally Advanced Rectal Cancer.

ABSTRACT: This open-label study will assess the efficacy and safety of Avastin (bevacizumab) plus Xeloda (capecitabine) in combination with standard technique radiotherapy of the pelvic region in the neo-adjuvant setting in patients with locally advanced primary rectal cancer. Patients will receive 4 courses of Avastin at a dose of 5 mg/kg intravenously (iv) every 2 weeks and for 38 days Xeloda at dose of 825 mg/kg twice daily orally, plus radiation therapy. After surgery, adjuvant treatment with 5-fluorouracil/leucovorin and, at the discretion of the investigator, with Avastin 5 mg/kg iv every 2 weeks for at least 6 months will be given.

DISEASE(S): Rectal Neoplasms,Patients With Locally Advanced, Non Metastatic, Resectable Primary Rectal Cancer Stage Ct3 Or Ct4 Who Are Subject To Combined Chemotherapy Of The Pelvic Region In The Pre-operative Setting.,Colorectal Cancer,Pazienti Con Carcinoma Rettale Primario Resecabile, Localmente Avanzato, Non Metastatico, In Stadio Clinico T3 O T4 Che Sono Candidati Ad Un Trattamento Combinato Chemioterapico E Radioterapico A Livello Della Regione Pelvica In Fase Pre-operatoria.,Rectal Cancer

PROVIDER: 2097067 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR